Wenn Sie das Fenster schließen, wird Ihre Konfiguration nicht gespeichert, es sei denn, Sie haben Ihren Artikel in die Bestellung aufgenommen oder zu Ihren Favoriten hinzugefügt.
Klicken Sie auf OK, um das MILLIPLEX® MAP-Tool zu schließen oder auf Abbrechen, um zu Ihrer Auswahl zurückzukehren.
Wählen Sie konfigurierbare Panels & Premixed-Kits - ODER - Kits für die zelluläre Signaltransduktion & MAPmates™
Konfigurieren Sie Ihre MILLIPLEX® MAP-Kits und lassen sich den Preis anzeigen.
Konfigurierbare Panels & Premixed-Kits
Unser breites Angebot enthält Multiplex-Panels, für die Sie die Analyten auswählen können, die am besten für Ihre Anwendung geeignet sind. Unter einem separaten Register können Sie das Premixed-Cytokin-Format oder ein Singleplex-Kit wählen.
Kits für die zelluläre Signaltransduktion & MAPmates™
Wählen Sie gebrauchsfertige Kits zur Erforschung gesamter Signalwege oder Prozesse. Oder konfigurieren Sie Ihre eigenen Kits mit Singleplex MAPmates™.
Die folgenden MAPmates™ sollten nicht zusammen analysiert werden: -MAPmates™, die einen unterschiedlichen Assaypuffer erfordern. -Phosphospezifische und MAPmate™ Gesamtkombinationen wie Gesamt-GSK3β und Gesamt-GSK3β (Ser 9). -PanTyr und locusspezifische MAPmates™, z.B. Phospho-EGF-Rezeptor und Phospho-STAT1 (Tyr701). -Mehr als 1 Phospho-MAPmate™ für ein einziges Target (Akt, STAT3). -GAPDH und β-Tubulin können nicht mit Kits oder MAPmates™, die panTyr enthalten, analysiert werden.
.
Bestellnummer
Bestellinformationen
St./Pkg.
Liste
Dieser Artikel wurde zu Ihren Favoriten hinzugefügt.
Wählen Sie bitte Spezies, Panelart, Kit oder Probenart
Um Ihr MILLIPLEX® MAP-Kit zu konfigurieren, wählen Sie zunächst eine Spezies, eine Panelart und/oder ein Kit.
Custom Premix Selecting "Custom Premix" option means that all of the beads you have chosen will be premixed in manufacturing before the kit is sent to you.
Catalogue Number
Ordering Description
Qty/Pack
List
Dieser Artikel wurde zu Ihren Favoriten hinzugefügt.
Spezies
Panelart
Gewähltes Kit
Menge
Bestellnummer
Bestellinformationen
St./Pkg.
Listenpreis
96-Well Plate
Menge
Bestellnummer
Bestellinformationen
St./Pkg.
Listenpreis
Weitere Reagenzien hinzufügen (MAPmates erfordern die Verwendung eines Puffer- und Detektionskits)
Menge
Bestellnummer
Bestellinformationen
St./Pkg.
Listenpreis
48-602MAG
Buffer Detection Kit for Magnetic Beads
1 Kit
Platzsparende Option Kunden, die mehrere Kits kaufen, können ihre Multiplex-Assaykomponenten in Kunststoffbeuteln anstelle von Packungen erhalten, um eine kompaktere Lagerung zu ermöglichen.
Dieser Artikel wurde zu Ihren Favoriten hinzugefügt.
Das Produkt wurde in Ihre Bestellung aufgenommen
Sie können nun ein weiteres Kit konfigurieren, ein Premixed-Kit wählen, zur Kasse gehen oder das Bestell-Tool schließen.
MABF2110-100UG
Sigma-AldrichAnti-EBOV GP Antibody, clone 5D2
Anti-EBOV GP, clone 5D2, Cat. No. MABF2110, is a mouse monoclonal antibody that detects envelope glycoprotein in Ebola virus and has been tested for use in ELISA, Immunocytochemistry, Immunoprecipitation, Neutralization, and Western Blotting.
More>>Anti-EBOV GP, clone 5D2, Cat. No. MABF2110, is a mouse monoclonal antibody that detects envelope glycoprotein in Ebola virus and has been tested for use in ELISA, Immunocytochemistry, Immunoprecipitation, Neutralization, and Western Blotting. Less<<
Envelope glycoprotein (UniProt: Q05320; also known as GP1,2; GP) is encoded by the GP gene (Gene ID: 911829) in Zaire Ebola virus. Ebola virus (EBOV) is a filovirus that is shown to cause severe viral hemorrhagic fever with high lethality. It has a single stranded, negative-sense RNA genome that encodes seven viral structural proteins including nucleoprotein, virion proteins, and glycoprotein. The glycoprotein is the most important protein involved in pathogenesis. It is a type I transmembrane surface protein shown to be responsible for receptor binding, viral entry, and cellular tropism. The GP gene is reported to undergo transcriptional editing to give rise to several glycosylated proteins, including the structural protein GP1,2, and the secreted non-structural glycoprotein (sGP). The GP is synthesized as a 676-amino acid polyprotein with a signal peptide (aa 1-32). This polyprotein is cleaved by the furin to yield two disulfide linked subunits known as GP1 (aa 33-501) and GP2 (aa 502-676), which together form the GP1,2 heterodimer. The GP1 acts as the receptor-binding subunit and GP2 as the membrane fusion subunit. The GP1 subunit is expressed on the cell surface with the C-terminus oriented toward the aqueous environment, while the N-terminus is bound to GP2 via disulfide bonds. The GP1 subunit contains the heavily glycosylated mucin-like domain (aa 305-485), which is responsible for its cytotoxic function. The glycoprotein contains two coiled coil regions (aa 554-595 and 615-634) that play a role in its oligomerization and fusion activity. When administered before virus challenge, clone 5D2 can provide complete protection from cytopathic effects. (Ref.: Qiu, X., et al. (2011). Clin. Immunol. 141(2); 218-227).
References
Product Information
Format
Purified
Presentation
Purified mouse monoclonal antibody IgG2a in PBS without azide.
Applications
Application
Anti-EBOV GP, clone 5D2, Cat. No. MABF2110, is a mouse monoclonal antibody that detects envelope glycoprotein in Ebola virus and has been tested for use in ELISA, Immunocytochemistry, Immunoprecipitation, Neutralization, and Western Blotting.
Key Applications
ELISA
Immunocytochemistry
Immunoprecipitation
Western Blotting
Neutralization Assay
Application Notes
ELISA Analysis: A representative lot detected EBOV GP in ELISA applications (Qiu, X., et. al. (2011). Clin Immunol. 141(2):218-27).
Immunocytochemistry Analysis: A representative lot detected EBOV GP in Immunocytochemistry applications (Qiu, X., et. al. (2011). Clin Immunol. 141(2):218-27).
Immunoprecipitation Analysis: A representative lot detected EBOV GP in Immunoprecipitation applications (Qiu, X., et. al. (2011). Clin Immunol. 141(2):218-27).
Western Blotting Analysis: A representative lot detected EBOV GP in Western Blotting applications (Qiu, X., et. al. (2011). Clin Immunol. 141(2):218-27).
Neutralizing Analysis: A representative lot provided complete protection from cytopathic effects when administed prior to virus challenge. (Qiu, X., et. al. (2011). Clin Immunol. 141(2):218-27).
Biological Information
Immunogen
Glycoprotein from Zaire Ebola virus, strain Mayinga, expressed in VSVdeltaG. Reverse genetics technique was used to create the recombinant virus VSVdeltaG/ZEBOV glycoprotein.
Clone
5D2
Concentration
Please refer to lot specific datasheet.
Host
Mouse
Specificity
Clone 5D2 is a mouse monoclonal antibody that detects envelope glycoprotein from Zaire Ebola virus.
Evaluated by ELISA with recombinant Ebola Virus Glycoprotein minus the transmembrane region (EBOV rGPdeltaTM).
ELISA Analysis: Various dilutions of this antibody detected rRecombinant Ebola Virus Glycoprotein minus the transmembrane region (EBOV rGPdeltaTM).
Usage Statement
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage Conditions
Stable for 1 year at -20°C from date of receipt. Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
Packaging Information
Material Size
100 μg
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Bestellnummer
GTIN
MABF2110-100UG
04054839750946
Documentation
Anti-EBOV GP Antibody, clone 5D2 Analysenzertifikate
Zaire ebolavirus (ZEBOV) can be transmitted by human-to-human contact and causes acute haemorrhagic fever with case fatality rates up to 90%. There are no effective therapeutic or prophylactic treatments available. The sole transmembrane glycoprotein (GP) is the key target for developing neutralizing antibodies. In this study, recombinant VSVΔG/ZEBOVGP was used to generate monoclonal antibodies (MAbs) against the ZEBOV GP. A total of 8 MAbs were produced using traditional hybridoma cell fusion technology, and then characterized by ELISA using ZEBOV VLPs, Western blotting, an immunofluorescence assay, and immunoprecipitation. All 8 MAbs worked in IFA and IP, suggesting that they are all conformational MAbs, however six of them recognized linearized epitopes by WB. ELISA results demonstrated that one MAb bound to a secreted GP (sGP 1-295aa); three bind to a part of the mucin domain (333-458aa); three MAbs recognized epitopes on the C-terminal domain of GP1 (296-501aa); and one bound to full length GP (VLPs/GP1,2 ΔTm). Using a mouse model these MAbs were evaluated for their therapeutic capacity during a lethal infection. All 8 MAb improved survival rates by 33%-100% against a high dose lethal challenge with mouse-adapted ZEBOV. This work has important implications for further development of vaccines and immunotherapies for ZEBOV infection.
